CoChat

MYC targeting by OMO-103 in solid tumors: a phase 1 trial

Open access
Garralda, Elena, Beaulieu, Marie-Eve, Moreno, Víctor, Casacuberta-Serra, Sílvia, Martínez-Martín, Sandra, Foradada, Laia, Alonso, Guzman, Massó-Vallés, Daniel, López-Estévez, Sergio, Jauset, Toni, Corral de la Fuente, Elena, Doger, Bernard, Hernández, Tatiana, Perez-Lopez, Raquel, Arqués, Oriol, Castillo Cano, Virginia, Morales, Josefa, Whitfield, Jonathan R., Niewel, Manuela, Soucek, Laura, Calvo, Emiliano · 2024 · Nature Medicine
Cited by 196

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Among the ‘most wanted’ targets in cancer therapy is the oncogene MYC, which coordinates key transcriptional programs in tumor development and maintenance. It has, however, long been considered undruggable. OMO-103 is a MYC inhibitor consisting of a 91-amino acid miniprotein. Here we present results from a phase 1 study of OMO-103 in advanced solid tumors, established to examine safety and tolerability as primary outcomes and pharmacokinetics, recommended phase 2 dose and preliminary signs of activity as secondary ones. A classical 3 + 3 design was used for dose escalation of weekly intravenous, single-agent OMO-103 administration in 21-day cycles, encompassing six dose levels (DLs). A total of 22 patients were enrolled, with treatment maintained until disease progression. The most common adverse events were grade 1 infusion-related reactions, occurring in ten patients. One dose-limiting toxicity occurred at DL5. Pharmacokinetics showed nonlinearity, with tissue saturation signs at DL5 and a terminal half-life in serum of 40 h. Of the 19 patients evaluable for response, 12 reached the predefined 9-week time point for assessment of drug antitumor activity, eight of those showing stable disease by computed tomography. One patient defined as stable disease by response evaluation criteria in solid tumors showed a 49% reduction in total tumor volume at best response. Transcriptomic analysis supported target engagement in tumor biopsies. In addition, we identified soluble factors that are potential pharmacodynamic and predictive response markers. Based on all these data, the recommended phase 2 dose was determined as DL5 (6.48 mg kg−1). ClinicalTrials.gov identifier: NCT04808362.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-024-02805-1

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Metadata

Authors
Garralda, E., Beaulieu, M.-E., Moreno, V., Casacuberta-Serra, S., Martínez-Martín, S., Foradada, L., Alonso, G., Massó-Vallés, D., López-Estévez, S., Jauset, T., Corral de la Fuente, E., Doger, B., Hernández, T., Perez-Lopez, R., Arqués, O., Castillo Cano, V., Morales, J., Whitfield, J. R., Niewel, M., Soucek, L., & Calvo, E.
Venue
Nature Medicine
Published
2024-02-06
Volume
30
Issue
3
Pages
762-771
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4391576268
Cited by
196
References
8
FWCI
30.08
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MYC targeting by OMO-103 in solid tumors: a phase 1 trial. https://app.cochat.ai/papers/10.1038/s41591-024-02805-1
The paper
Garralda, E., Beaulieu, M.-E., Moreno, V., Casacuberta-Serra, S., Martínez-Martín, S., Foradada, L., Alonso, G., Massó-Vallés, D., López-Estévez, S., Jauset, T., Corral de la Fuente, E., Doger, B., Hernández, T., Perez-Lopez, R., Arqués, O., Castillo Cano, V., Morales, J., Whitfield, J. R., Niewel, M., . . . Calvo, E. (2024). MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nature Medicine. https://doi.org/10.1038/s41591-024-02805-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.